Rockville, United States
MacroGenics, Inc. is at the forefront of developing immunotherapeutics aimed at combating autoimmune disorders, cancer, and infectious diseases. With a focus on next-generation antibody-based technologies, the company has built a robust pipeline of product candidates targeting cancer treatment.
Founded in 2000 and headquartered in the United States, MacroGenics operates within the biotechnology, healthcare, and manufacturing industries. With a dedicated team of over 300 employees, the company's corporate culture emphasizes innovation, open communication, and teamwork. This innovative spirit has attracted multiple partnerships with leading pharmaceutical and biotechnology companies worldwide, leveraging their competitive advantage in cutting-edge therapies.
The firm's commitment to professional development is evident in their emphasis on employee growth as a key asset. Despite the last known investment in March 2019 having undisclosed details, MacroGenics holds a strategic position for future investment opportunities within the high-demand biotech landscape.
